In the present study, we aim to compare the rationality of proposed N classification based on the number of metastatic lymph nodes (LNs) with the current one. A total of 509 penile cancer patients at our institute were analyzed. Univariable and multivariable statistical analyses were used to assess cancer-specific survival (CSS) in 2 staging systems. Harrell's concordance index was applied to evaluate predictive accuracy of the current and proposed N classification in predicting CSS. We propose a new classification: pN1 (metastasis in 1-2 regional LNs), pN2 (metastasis in 3 regional LNs, or 3 or fewer regional lymph nodes with extranodal extension), and pN3 (metastasis in 4 or more regional LNs). According to the current and proposed N classification, the 5-year CSS of penile cancer patients with pN1, pN2 and pN3 was 85.8%, 39.0%, and 19.7%; and with pN1, pN2 and pN3 was 79.8%, 39.3% and 15.3%, which almost all showed significant difference (P < .001, P = .259) (P < .001, P < .001). Multivariable predictive accuracy of the proposed and current N staging was 76.48% and 70.92% (5.56% gain; P < .001). With a multivariable model of clinical features, both current (hazard ratio [HR], 7.761, 10.612; P < .001, P < .001) and proposed N stages (HR, 3.792, 3.971; P < .001, P < .001) exhibited independent effects on survival. The proposed N classification is superior to the current one, which is simpler and provides more accurate prognosis.
| INTRODUCTION
In the present study, we aimed to compare the rationality of a proposed N classification based on the number of metastatic lymph nodes (LNs) with the current one. A total of 509 penile cancer patients at our institute were analyzed. Univariable and multivariable statistical analyses were used to assess cancer-specific survival (CSS) in 2 staging systems. Harrell's concordance index was applied to evaluate the predictive accuracy of the current and proposed N classifications in predicting CSS. We propose a new classification: pN1, metastasis in 1 or 2 regional LNs; pN2, metastasis in 3 regional LNs, or 3 or fewer regional lymph nodes with extranodal extension; and pN3, metastasis in 4 or more regional LNs. According to the current N classification, the 5-year CSS of penile cancer patients with pN1, pN2, and pN3 was 85.8%, 39.0%, and 19.7%; with the proposed N classification, the 5-year CSS with pN1, pN2, and pN3 was 79.8%, 39.3% and 15.3%. All of these comparisons between pN1 and pN2 of current classification (P < .001), between pN1 and pN2 (P < .001), pN2 and pN3 (P < .001) of proposed classification showed significant statistical difference except comparison between pN2 and pN3 of current classification (P = .259). Multivariable predictive accuracy of the proposed and current N staging was 76.48% and 70.92% (5.56% gain; P < .001). With a multivariable model of clinical features, both current (hazard ratio, 7.761, 10.612; P < .001, P < .001) and proposed N stages (hazard ratio, 3.792, 3.971; P < .001, P < .001) showed independent effects on survival. The proposed N classification is superior to the current one in that it is simpler and provides more accurate prognosis.
The 8th edition of the AJCC's N staging system for penile cancer was published with 1 change: metastasis in unilateral 2 inguinal LNs was incorporated into pN1. Generally, the system follows the 2009 TNM clinical and pathological classification. 1, 2 The current N classification was based mainly on a single study with some limitations. Our institution has followed a standardized follow-up protocol for 18 years. Patients were, in general, assessed at 3-month intervals for the first 2 years following surgery, semiannually for the years 3-5, and annually thereafter. Follow-up evaluation included physical examination of the penis and the groin, ultrasound, and pelvic computed tomography. The survival interval was defined from the date of surgery to the date of death or the last follow-up. Cancer-specific survival was the primary end-point, and the cause of death was determined by treating physicians by chart review corroborated by death certificates, or by death certificates alone. 12 Our follow-up assessment ended in January 2017.
| Current and proposed N staging systems
The definitions of the current and proposed N staging systems are listed in Table 1 .
| Statistical analysis
Continuous parametric variables were recorded as the mean value AE SD; the median value and interquartile ranges were Harrell c-index were used in the prognostic models. 13 Predictive accuracy was evaluated by the c-index, which ranges from 0.5 (no predictive ability) to 1.0 (perfect discrimination). All reported Pvalues are two-sided, with P < .05 indicating statistical significance.
All data analyses were undertaken with SPSS 19.0 (IBM, Armonk, NY, USA) and R 3.2.3.
We acquired the Research Data Deposit approval number RDDA2017000381 on the Research Data Deposit public platform (www.researchdata.org.cn).
3 | RESULTS proposed N classification. Moreover, according to our statistics, we found that no PLNM was detected in patients with 2 positive LNs.
| Patient characteristics

| Prognosis in relation to unilateral and bilateral LNM
In 147 patients with 2 or more positive LNs, 66 and 81 patients were found to have unilateral and bilateral LNM, respectively. There was no survival difference between these 2 groups (37.9% vs 36.9%, P = .535; Figure 1B ). According to our proposed N classification, no survival differences were reported between the patients with unilateral vs bilateral LNM in pN1, pN2, and pN3 (P = .470, .404, and .522, respectively) (Figures S1, S2, S3).
| Prognosis between the current and proposed pN3
Our statistics show that there were 32 patients with PLNM in our study, among whom 26 patients (81.25%) were found to have 4 or more positive LNs. Another 6 patients (18.75%) were found to have 3 positive LNs. The 5-year CSS of patients with PLNM and 3 or 4 or more positive LNs was 25.0% and 12.0%, respectively, representing a statistically significant difference (P = .025; Figure 1C ). Moreover, the 5-year CSS of the current and proposed pN3 was 18.7% and 15.3%, respectively. In addition, the proposed pN3 group showed significant homogeneity in their prognosis (P = .480; Figure S4 ). In our proposed pN3, the 5-year CSS of the 26 patients with PLNM and 47 patients without PLNM was 19.0% and 12.4%, respectively, showing no statistical difference (P = .333; Figure 1D ). Patients were treated at the Sun Yat-Sen University Cancer Center (Guangzhou, China). AJCC, American Joint Committee on Cancer; BMI, body mass index; ENE, extranodal extension; PLNM, pelvic lymph node metastasis. Table 3 shows the relationship between the AJCC 8th edition N classification and our proposed N classification. Figure 2A analyzes the association between the number of positive LNs and survival for all patients. We observed a marked linear trend for an increasing number of metastatic LNs correlated with decreasing survival times. Survival curves showed no significant difference between patients with 1 or 2 positive nodes (P = .319). However, significant differences were observed between patients with 2 vs 3 metastatic nodes, and 3 vs 4 positive nodes (P = .036 and P < .001, respectively), but no statistically significant difference was found between those with 4 vs 5 or more positive nodes (P = .507). Figure 2 shows survival curves based on the current and proposed N staging systems. According to the current N classification, the 5-year CSS of patients with penile cancer with pN1, pN2, or pN3 was 85.8%, 39.0%, and 19.7%, respectively, which represented a significant difference (P < .001 and P = .259; Figure 2B ). On the basis of our proposed N classification, the 5-year CSS for pN1, pN2, and pN3 was 79.8%, 39.3%, and 15.3%, respectively. Statistically significant differences were found between these 2 classifications, which also showed good survival stratification (P < .001 and P < .001; Figure 2C ). | 767 subgroups of the current pN2 and pN3 groups, which means that heterogeneity was found in the current pN2 and pN3 groups (P < .001 and P = .002, respectively; Figures S6, S7 ). The proposed pN1 and pN2 groups showed heterogeneity in their prognosis (P = .034 and P = .002, respectively; Figures S8, S9 ). The current pN1
| Correlation with CSS
and pN2 groups were the same as the proposed pN1 and pN2 patient cohorts with regard to homogeneity, whereas the proposed pN3 patient group was more homogeneous than the current pN3 cohort.
In the univariable analysis, primary T stage (P = .002), grade (P = .009), number of positive LNs (P < .001), and side involvement (P = .03) were related to CSS.
In multivariable Cox regression analysis adjusting for the effects of established clinicopathologic parameters including pT stage and tumor grade, both N classifications were independent markers for cancer-specific mortality (Table 4) 
| DISCUSSION
The current TNM classification for penile cancer was based mainly on a notable study that had some limitations, including a long timespan of treating patients, a lack of specified number of retrieved LNs, and an imbalanced distribution of patients. 3 In researching our proposed classification, we found that there was room for improvement regarding clinical usefulness, predictive accuracy, and simplicity. Finally, our study found no significant difference in the CSS of patients with penile cancer between those with metastasis in 3 regional LNs and those with metastasis in 3 or fewer regional LNs with ENE. Previous studies have assessed ENE as a prognostic factor. 12, 19, 20 However, most ENE is associated with fused LNs, which makes it difficult to count the number of positive LNs precisely.
Among the cancers with number-based N staging systems, extranodal tumor deposits were described only in colon cancer. In colon cancer, tumor deposit in the subserosa, mesentery, or non-peritonealized pericolic or perirectal tissues without regional nodal metastasis was defined as N1c, while metastasis in 1 regional LN and metastasis in 2 or 3 regional LNs was defined as N1a and N1b, respectively. With regard to the N classification of colon cancer, we compared the CSS in patients with 3 positive LNs with CSS in patients with 3 or fewer regional LNs with ENE, which showed no significant survival difference.
Thus, they are both defined as pN2 in our proposed classification. On the basis of our findings, we propose a simpler and more precise N classification based only on the number of positive LNs.
We acknowledge that our study is not without limitations, most notably, its retrospective design. However, the potential flaws of a retrospective study have been minimized with systematic re-evaluation of each specimen by a dedicated uropathologist blinded to clinical outcomes. Moreover, a large sample size and standard treatment approach of our study further reduce shortcomings of retrospective design. Secondly, adjuvant chemotherapy and pelvic lymphadenectomy may have an impact on survival. According to the current guidelines, for patients with 2 positive LNs, we perform pelvic lymphadenectomy and adjuvant chemotherapy, 21 which may affect their survival and lead to selection bias. However, for patients with 2 positive LNs, there was no ENE or PLNM. The final potential limitation is a relatively short follow-up time. The median time was 33 months, which may result in length time bias. It's possible that the rate of regional recurrence was underestimated. However, a prior study reported that local or regional nodal recurrences usually occur within 2 years of primary treatment. 18 Further research involving longer follow-up may help reduce bias.
In conclusion, the number-based proposed N classification represents a prognostic factor as powerful as the current N staging systems. 
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